NCT Number: NCT05075577
Phase: Phase 1|Phase 2
Trial Summary: This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjec – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): ESSA Pharmaceuticals
Acronym:
EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives